Latest news with #JocelyneBloch
Yahoo
21-05-2025
- Business
- Yahoo
ONWARD Medical Advances Brain-Computer Interface Leadership with Fourth and Fifth Successful BCI Implants
Groundbreaking procedures extend ONWARD's leadership in the rapidly emerging brain-computer interface (BCI) field ARC-BCI Therapy is designed to restore thought-driven movement after spinal cord injury and other movement disabilities ONWARD's BCI breakthroughs were recently featured on CBS 60 Minutes with Anderson Cooper EINDHOVEN, the Netherlands, May 21, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury (SCI) and other movement disabilities, today announces that two additional individuals with spinal cord injury have received ONWARD's investigational ARC-BCI® Therapy, bringing the total number of successful implants to five. These achievements further reinforce ONWARD's leadership in developing BCI-enabled movement solutions for individuals with spinal cord injury. Both procedures were performed at Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland, under the direction of Jocelyne Bloch, MD, Chief of Neurosurgery. The fourth procedure involved a 48-year-old man with an injury sustained in 2024. The fifth procedure was performed on a 37-year-old woman with an injury from 2011. Detailed results for both participants are expected to be shared in a peer-reviewed scientific publication, consistent with the Company's longstanding reputation for scientific rigor. "With five successful procedures now completed, we are gaining important information about this potentially transformative therapy for individuals with spinal cord injury," said Dave Marver, CEO of ONWARD Medical. "Each procedure advances our understanding and refines our approach, bringing us closer to our vision to make thought-driven movement a reality for people living with paralysis." The investigational ARC-BCI System pairs the Company's BCI with its ARC-IM® System, an implanted spinal cord stimulation technology, to create the ONWARD DigitalBridge™, a wireless connection between the brain and the body that enables thought-driven movement after paralysis. It uses artificial intelligence (AI) to decode brain signals and translate intention into movement. The ARC-BCI System was awarded Breakthrough Device Designation (BDD) by the US Food and Drug Administration (FDA) in February 2024. These latest implants are part of ongoing clinical feasibility studies investigating the use of thought-driven spinal cord stimulation after spinal cord injury. The research is supported by grants from the European Innovation Council and the Christopher & Dana Reeve Foundation under the oversight of Grégoire Courtine, PhD, Jocelyne Bloch, MD, and Guillaume Charvet, Head of Neurotechnology at CEA. "We continue to have excellent experience with ONWARD ARC-BCI Therapy, which provides the data and resolution we need with a less invasive surgery than is required with other BCI platforms,' said Jocelyne Bloch, MD. 'Our research is progressing well, and the study participants are showing improvements that meet or surpass our expectations. We look forward to sharing more details in a peer-reviewed setting." ONWARD ARC-BCI Therapy was recently featured on CBS 60 Minutes with Anderson Cooper, one of the most respected and longest-running US news programs. The segment highlighted the experience of study participants who received the breakthrough therapy. The complete 60 Minutes segment is available for viewing on the CBS News website. A 60 Minutes Overtime segment is also available for viewing here. About ONWARD Medical ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury (SCI) and other movement disabilities. Building on more than a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company has developed ARC Therapy, which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA). The Company's ARC-EX System is cleared for commercial sale in the US. In addition, the Company is developing an investigational implantable system called ARC-IM with and without an implanted brain-computer interface (BCI). Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY). To learn more about ONWARD Medical's commitment to partnering with the spinal cord injury community to develop innovative solutions for restoring movement, function, and independence after spinal cord injury, please visit To be kept informed about the Company's technologies, research studies, and the availability of therapies in your area, please complete this webform. For Media Inquiries: Sébastien Cros, VP Communications media@ For Investor Inquiries: investors@ Disclaimer Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Trademarks: ONWARD, ARC-EX, ARC-IM, ARC-BCI, and the stylized O-Logo are proprietary and registered trademarks of ONWARD Medical. Unauthorized use is strictly prohibited. ARC-EX Indication for Use (US): The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive). Other Investigational Products: All other ONWARD Medical devices and therapies including ARC-IM and ARC-BCI are investigational and not available for commercial use.
CBS News
11-05-2025
- Health
- CBS News
Trying to restore bodily functions after spinal cord injuries
Anderson Cooper: This week on 60 Minutes, we're doing a story about efforts to help people who are paralyzed with severe spinal cord injuries develop the ability to walk again. And not just walk again, but actually walk using their thoughts to control the movement of their limbs. Anderson Cooper: A French neuroscientist, Gregoire Courtine, and a Swiss neurosurgeon, Dr. Jocelyne Bloch, have been working together in their lab called NeuroRestore in Lausanne, Switzerland. And they have developed something they call a digital bridge. Dave Marver: So, if you have an injury, the communication between the brain and the spinal cord that controls movement and other functions, it's interrupted. Anderson Cooper: Dave Marver is the CEO of Onward Medical, which is a company that Dr. Bloch and Gregoire Courtine have formed to get this technology out of the lab, and into the marketplace Dave Marver: So, a digital bridge actually circumvents that injury. It sends signals wirelessly from the brain to the intact, healthy part of the spinal cord on the other side of the injury to enable a person to move or have other critical functions. Anderson Cooper: I think if you haven't experienced paralysis, you may think wanting to walk again, that's the number one thing. There's a whole range of issues which are really difficult for somebody who is paralyzed. Dave Marver: I think the public views walking again, as the top priority. It's well down the list. They want to go to the bathroom without inserting a catheter. They want sexual function back. They want to normalize their blood pressure, their body temperature. These are things that impact them every day for hours of every day. Blood pressure regulation's a big problem. So, what happens is, after a spinal cord injury, people often have very low blood pressure. It means that it's difficult for them to sit upright like this and have a conversation or have a meal with loved ones and friends without feeling faint. It can also take them an hour to just transition from bed to chair in the morning because they're continually feeling light-headed and faint. Jocelyne Bloch: To regulate the blood pressure, you need your nervous system, too, that is also going through the spinal cord. Gregoire Courtine: With the spinal cord stimulation, there is a very specific region of the spinal cord that we can target with the stimulation that is normally elevating blood pressure. So, we adapted our system to stimulate this region, and we are able to alleviate this hypotensive complication due to a spinal cord injury. And we are playing on the same principle for the improvement of the bladder function, which is a big problem for people with a spinal cord injury. Anderson Cooper: Spinal cord stimulators may show some promise in helping people with Parkinson's Disease. It's still very early clinical trials. But it's helping people regain a certain amount of mobility, which for people in later stages of Parkinson's can be a huge issue. Gregoire Courtine: In the case of people with Parkinson's disease, the brain sends crumbled signals, although the spinal cord is fully intact. So we thought, "Can we not use the same principle to activate the spinal cord, and this way regulate walking?" And it was absolutely incredible. The first observation, it's, like, you turn on the stimulation because the spinal cord's intact. The patient, with the stimulation, was walking almost normally. Anderson Cooper: Is that with the implant in the brain, or just the stimulation? Gregoire Courtine: In this case, it was only with the spinal cord stimulation. Anderson Cooper: I just want to make sure people know that there's a long way to go before something like this could be more widely accessible. But that is certainly the hope for Bloch and Courtine. Jocelyne Bloch: That would be success. Having the possibility to apply the therapy to many patients would be very nice. Gregoire Courtine: The hurdle now is primarily executing a clinical trial to show safety and efficacy, get approval by the FDA and the European Union and make sure that the therapy's not too complicated so that other centers can apply it to their patient. Jocelyne Bloch: The ideal world is simplicity. It should be very easy for any patient to use the therapy. Anderson Cooper: In an ideal scenario, what does this look like ten years from now? Dave Marver: What I'd like is for somebody with a spinal cord injury to be able to engage in a conversation or discussion with their doctor and identify what they want to see fixed or recovered. To be able to almost [have] a menu. "I want to restore my hand function. I want to normalize my blood pressure. I want to address my incontinence or sexual function." And our therapies will offer the opportunity to fix every one of those things. That's our vision. The video above was produced by Brit McCandless Farmer and edited by Scott Rosann.
CBS News
11-05-2025
- Health
- CBS News
Injuries left them paralyzed. An early promising clinical trial is helping them walk short distances again.
For those who've suffered a traumatic spinal cord injury and are paralyzed, there's rarely encouraging news, which is why what's happening in early clinical trials in a research lab in Lausanne, Switzerland is so remarkable. A renowned French neuroscientist, Gregoire Courtine, and Swiss neurosurgeon, Dr. Jocelyne Bloch, have implanted a small stimulation device on the spine of paralyzed patients, helping them once again stand up and walk. What's even more surprising is their newest innovation, which uses an implant in the skull that enables patients to move their paralyzed legs or arms, just by thinking about it. When we visited their lab, NeuroRestore, in March, they were working with a 39-year-old woman whose spinal cord was severed six and a half years ago. She'd been told she'd never walk again. Marta Carsteanu-Dombi is the most severely paralyzed patient who's enrolled in this clinical trial at NeuroRestore to regain mobility in her legs. She has no feeling below her waist and isn't able to keep her balance. Just sitting up on her own is a challenge. In 2018, Marta was a new mom, working at a German tech company, when she began training with her husband for an IronMan competition. She was in the best shape of her life, but during the bike portion of the race she suffered a devastating accident. Anderson Cooper: You were found– Marta Carsteanu-Dombi: Near a tree. Anderson Cooper: --near a tree? Marta Carsteanu-Dombi: Yes. So– Anderson Cooper: And your back hit the tree. Marta Carsteanu-Dombi: We're hypothesizing what happened, right, 'cause nobody saw me. So, I must have had a pretty tough collision because my spine basically broke, like, two dimensions. Marta Carsteanu-Dombi 60 Minutes Her spinal cord injury was so severe doctors said there was no sign of nerve connections left to her lower body. She'd also broken eight ribs, punctured her lungs, and was bleeding internally. She needed emergency surgery and doctors told her family she might not survive. Anderson Cooper: You came out of the surgery-- I understand you wrote a message to your mom. Marta Carsteanu-Dombi: So the surgery took about seven to eight hours, and I was intubated; I could not talk. And my mom, you can imagine, was in tears. And I just wrote to her, "I'm strong." That strength has been tested. Marta spent 10 days in intensive care and four and a half months in a rehab hospital learning to adapt to her new life in a wheelchair. Anderson Cooper: Traditionally, if someone gets a spinal cord injury, what are the treatment options for them? Jocelyne Bloch: You have to do a little bit of physiotherapy, get into a wheelchair and then you go back home. And that's all. Anderson Cooper: That's it? Jocelyne Bloch: That's it. And that was for many years the only option. Dr. Jocelyne Bloch and Gregoire Courtine have been at the forefront of researchers trying to expand those options since 2012. Their lab, near Lake Geneva, is a collaboration between the Swiss Federal Institute of Technology, Switzerland's MIT, and the Lausanne University hospital. That's where they've implanted eight paralyzed patients with a device that allows them to stimulate their spinal cords, enabling them to stand, take steps with a walker, and lift weights. Some can even climb stairs. They use a button to activate the stimulation. And now, thanks to Courtine and Bloch's latest technology, five other patients can move their paralyzed limbs using their own thoughts. It's called a digital bridge, and it wirelessly connects a patient's brain to their spinal cord stimulator. Gregoire Courtine: Normally there is a-- a direct communication between the brain and the spinal cord. Anderson Cooper: For me to walk, my brain just automatically tells my legs to walk? Jocelyne Bloch: Uh-huh. French neuroscientist Gregoire Courtine and Swiss neurosurgeon Dr. Jocelyne Bloch 60 Minutes Gregoire Courtine: But because of the spinal cord injury the signal is interrupted. So we are aiming to bridge-- bypass the injury by having a direct digital connection between the brain and the region of the spinal cord that control leg movement. To do that, Dr. Bloch implants a small titanium device, originally developed by a French research institute, in the patient's skull directly over their motor cortex, the area of the brain responsible for controlling movement. Gregoire Courtine: You see you have the 64 electrodes. Anderson Cooper: And so each of these is what? Jocelyne Bloch: It's electrode that are recording populations of neurons underneath. And you can immediately see which one are the best correlated to certain movements. Gregoire Courtine: Like the hip is here, and then the knee is here, and then the ankle is here, etc. Jocelyne Bloch: Yeah, yeah. When a patient thinks about moving a limb, those electrodes record the brain's activity. Then a computer uses artificial intelligence to translate the recordings into instructions for the stimulation device implanted on the spinal cord. That device sends electrical pulses activating muscles in the legs or arms. All of it happens in about half a second. Gert-Jan Oskam was the first person to get the "digital bridge" four years ago after he was paralyzed in a bike accident. We met him for a walk by Lake Geneva. Anderson Cooper: So now the stimulation is on? Gert-Jan Oskam: Now it's on, yes. Anderson Cooper: Do you feel it at all in your body? Gert-Jan Oskam: I do feel a little tingling sensation from the stimulation with my brain. Dutch man Gert-Jan Oskam can now walk up to 450 feet. His headpiece powers the implant in his skull, and on his walker is the computer. It's cumbersome and tiring, physically and mentally, but he can walk up to 450 feet. Anderson Cooper: It's incredible to me though that you can continue talking with me even though this machine is reading the signals from your brain. Gert-Jan Oskam: It's able to discriminate walking and talking at the same time. That's-- that's incredible. Anderson Cooper: For somebody who has not been able to control their movements, to suddenly be able to control their movement, I mean, that's-- Jocelyne Bloch: Yeah. There is this initial phase of surprise, you know, when they realize that it's-- they are giving the order and it's happening. You know? Gregoire Courtine: They are like, "Did I do that? Like, is it me or you actually stimulate it, no?" I say, "No, you did it." Anderson Cooper: They think you're pressing a button somewhere and doing it? Jocelyne Bloch: Yeah, yeah, yeah. Gregoire Courtine: They don't understand 'cause they've been paralyzed for so many years. Marta got the digital bridge implanted in September. She's worked with a team of engineers and physical therapists to figure out how much electrical stimulation is needed to move her legs. Gregoire Courtine: Nice. Marta Carsteanu-Dombi: Yeah, it's good. Gregoire Courtine: And up. Anderson Cooper: So that's the stimulation-- the electrical stimulation is making the leg move. Gregoire Courtine: Yeah, Marta is completely paralyzed. But Marta's also had to teach herself to think about moving the exact same way every time, so the AI can recognize her thoughts. She practiced at first with this avatar. Anderson Cooper: You have to relearn or rethink how to walk. Marta Carsteanu-Dombi: Exactly. So we were experimenting a little bit. What do I think about? Is it I think about the hip being contracted? Do I think about the knee lifting up? Do I think about the ankle? To show us how she does that, they disconnected her skull implant from her spinal cord stimulator and connected it to this exoskeleton. Anderson Cooper: You can control this with your thoughts right now. Marta Carsteanu-Dombi: Yeah. If I want to do a right movement, right hip flexion, it does a right hip flexion. Anderson Cooper: You're not pressing any buttons– Marta Carsteanu-Dombi: No. Anderson Cooper: --or anything. You're just thinking. Marta Carsteanu-Dombi: Sure. Anderson Cooper: Can you look at me without looking at it and just- Marta Carsteanu-Dombi: Do a right one? Yes. I think it works. Anderson Cooper: Yeah. Gregoire Courtine: It does work. Marta Carsteanu-Dombi 60 Minutes After training with the digital bridge for just two days, Dr. Jocelyne Bloch and Gregoire Courtine, or G as Marta calls him, put her to the test- eager to see if she could take some steps. Marta Carsteanu-Dombi: Jocelyne and G come in and it's like, "Okay, show off. So what can you do?" Anderson Cooper: They said, "Show off?" Marta Carsteanu-Dombi: Yeah, yeah. Anderson Cooper: Were you ready to show off? Marta Carsteanu-Dombi: I did not know if I'm able to show off. This was the thing. Using a harness to support about half her body weight and physical therapists to help place her feet on the ground, Marta took her first steps. Despite having no sensation below her waist, she was able to move her paralyzed legs with her thoughts. Anderson Cooper: What was that like? Marta Carsteanu-Dombi: Gaining some superpower. A power that I did not have before. And now with these implants, you know, it's-- I'm a real Ironwoman. When we were there in March, Marta wasn't able to walk on her own yet, but she said she'd already regained something she'd lost. Marta Carsteanu-Dombi: It's giving me my perspective back. Standing up again and looking people in the eye, that's different. Anderson Cooper: A difference in how you think about yourself or in how others see you– Marta Carsteanu-Dombi: Both– Anderson Cooper: --or how you interact in the world? Marta Carsteanu-Dombi: Everything. Everything. Arnaud Robert: You leave the hospital on your wheelchair and you notice the different looks. Anderson Cooper: Right away you noticed? Arnaud Robert: Yeah. Scared looks. Also, a lot of smiles that are a little bit too long. Arnaud Robert 60 Minutes Those well-meaning smiles reminded Arnaud Robert, who's quadriplegic, how much his life had changed. A Swiss journalist, he'd spent decades traveling the world, but three years ago he slipped on a patch of ice and was instantly paralyzed from the neck down. He regained some function in his right arm with physical therapy, but wanted to see if the digital bridge could help him with his left. Anderson Cooper: Opening and closing the hand is far more complex than walking? Gregoire Courtine: It is, because of the possibility to access a different muscle individually. Jocelyne Bloch: The hand is tricky with all these different little muscles. It's very subtle. But after surgery and training at Courtine and Bloch's lab for eight months, he was able to use his left hand to help hold a glass and type. Arnaud Robert: Even to be able to move my fingers, this is something that I couldn't do. And, of course, moving the-- the arm like that, this is something that I couldn't do either. Anderson Cooper: That's incredible. Arnaud Robert: It's really incredible. I mean, I don't want to pretend that I'm using this left arm on a daily base. There is a long, long way to get it functional for every quadriplegic in the world. But it was certainly a success, because I see that I can do things that I wouldn't-- I was not able to do before. But something else has happened as well: after using the digital bridge over time, both Arnaud and Gert-Jan have improved their ability to move their paralyzed limbs, even when the system is turned off. Anderson Cooper: How is that possible? What happened? Jocelyne Bloch: That was also our questions. And we could not do much in a human being to understand it. Since it wasn't possible for them to see the changes in their patients' spinal cords at a microscopic level, they did studies in animals to understand what was happening. Gregoire Courtine: What we understood was completely unexpected, that this training enabled the growth of new nerve connection. So new nerves started growing. And they grow on one very specific type of neuron that is uniquely equipped to repair the central nervous system. Jocelyne Bloch: So we also observed that the less the severity of the spinal cord lesion is, the, the better the regrowth happens. You know? If it's a complete spinal cord injury, it will be hard to regrow. But, indeed, there is something happening. How well the digital bridge works still needs to be studied in a lot more patients. They hope to launch clinical trials in the U.S. in the next two to three years. The FDA has already designated it as a breakthrough device, which will prioritize the review process, and Courtine and Bloch have co-founded a company called Onward Medical to bring this technology out of the lab, making it faster, smaller, and widely available. Marta Carsteanu-Dombi: It's not changing my everyday in ways people might think, "Oh, she's-- she's getting back her life she had before." So as long as it makes me feel good, that I can stand up and hug my husband or hug somebody that I love, that means a lot. Anderson Cooper: What's your goal? Marta Carsteanu-Dombi: To go out in the park, and just stand up and do some steps with my family. It's not a stroll in the park how it would look for most other people. But for me it's just good enough to make me happy. After six months of hard work, just before Marta was to return to her family, she did what doctors years ago told her she never would: she took a few steps. No harness to hold her, just her walker and her iron will. Produced by Nichole Marks. Associate producer, John Gallen. Broadcast associate, Grace Conley. Edited by Peter M. Berman.
Yahoo
04-03-2025
- Health
- Yahoo
ONWARD Medical to Advance Parkinson's Disease Pipeline with Support from The Michael J. Fox Foundation and US Department of Defense
The Michael J. Fox Foundation for Parkinson's Research is supporting a study addressing mobility challenges in Parkinson's disease; the first participant was enrolled in late 2024 A US Department of Defense grant will support a study addressing blood pressure instability; first enrollment is expected in 1H 2025 These studies both explore whether the ONWARD ARC-IM System has the potential to offer benefit beyond spinal cord injury EINDHOVEN, the Netherlands, March 04, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announces two new grants to support early clinical feasibility studies using its investigational ONWARD ARC-IM System to explore the technology's potential to help people with Parkinson's disease. The Michael J. Fox Foundation for Parkinson's Research (MJFF) awarded a $1M grant to researchers Jocelyne Bloch, MD and Grégoire Courtine, PhD of NeuroRestore to support a clinical feasibility study with 6 participants to explore whether the ONWARD ARC-IM System can address mobility challenges in Parkinson's. The study is underway with the first participant implanted in late 2024. More than 90% of people living with Parkinson's experience walking and balance dysfunction, and approximately 60% experience annual falls.1 Motor impairments severely impact quality of life, often leading to loss of independence and increased risk of injury.2 Mobility issues are seldom sufficiently addressed with prevailing treatments, underscoring the urgent need for more effective therapies in Parkinson's.3 The study will build on findings previously published by Courtine and Bloch in Nature Medicine in November 2023. In that study, ARC-IM Therapy was shown to improve mobility and balance, and reduce freezing-of-gait after Parkinson's. US Department of Defense Parkinson's Research Program Grant This approximately $1.5M grant was awarded to ONWARD and NeuroRestore. It will support a clinical feasibility study with 5 participants to explore the ability of the ONWARD ARC-IM System to address blood pressure instability in Parkinson's. The study is expected to commence in the first half of 2025. Approximately 800,000 people in the US and Europe are challenged by blood pressure issues resulting from Parkinson's.4 ONWARD previously received a grant from the US Defense Advanced Research Projects Agency (DARPA), part of the US Department of Defense, to support development of its investigational ARC-IM System to address blood pressure instability in spinal cord injury. 'The versatility and promise of the ONWARD ARC-IM System has been validated by grants from these distinguished organizations, supporting research to determine if our technology can be leveraged beyond spinal cord injury,' said Dave Marver, CEO of ONWARD Medical. "There are 10 million people worldwide living with Parkinson's and we are hopeful the ARC-IM System may offer them new and powerful therapeutic options.' The ARC-IM System is designed to deliver targeted, personalized spinal cord stimulation to restore function and movement after spinal cord injury and other movement disabilities. The System consists of an implantable neurostimulator that generates precise electrical stimulation delivered by a lead placed on the spinal cord. Together, they are designed to deliver ARC Therapy to the area of the spinal cord that is responsible for movement or restoration of autonomic function. To be kept informed about the Company's technologies, research studies, and the availability of therapies in your area, please complete this webform. About ONWARD Medical ONWARD Medical is a medical technology company creating therapies to restore movement, function, and independence in people with SCI and other movement disabilities. Building on more than a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company has developed ARC Therapy, which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA). The Company's ARC-EX System is now cleared for commercial sale in the US. In addition, the Company is developing an investigational implantable system called ARC-IM with and without an implanted brain-computer interface (BCI). Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD). For more information, visit and connect with us on LinkedIn and YouTube. To be kept informed about the Company's technologies, research studies, and the availability of therapies in your area, please complete this webform. For Media Inquiries:media@ For Investor Inquiries:Investors@ Disclaimer Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. ARC-EX Indication for Use (US): The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive). Other Investigational Products: All other ONWARD Medical devices and therapies including ARC-IM and ARC-BCI are investigational and not available for commercial use. Trademarks: ONWARD, ARC-EX, ARC-IM, ARC-BCI, and the stylized O-Logo are proprietary and registered trademarks of ONWARD Medical. Unauthorized use is strictly prohibited. 1Stolze, Henning et al. 'Prevalence of gait disorders in hospitalized neurological patients.' Movement disorders: official journal of the Movement Disorder Society vol. 20,1 (2005): 89-94. doi:10.1002/mds.20266. Ge, Hong-Liang et al. 'The prevalence of freezing of gait in Parkinson's disease and in patients with different disease durations and severities.' Chinese neurosurgical journal vol. 6 17. 14 May. 2020, doi:10.1186/s41016-020-00197-y Allen, Natalie E et al. 'Recurrent falls in Parkinson's disease: a systematic review.' Parkinson's disease vol. 2013 (2013): 906274. doi:10.1155/2013/906274. 2 Schrag, A et al. 'What contributes to quality of life in patients with Parkinson's disease?' Journal of neurology, neurosurgery, and psychiatry vol. 69,3 (2000): 308-12. doi:10.1136/jnnp.69.3.308. Bloem, B R et al. 'Prospective assessment of falls in Parkinson's disease.' Journal of neurology vol. 248,11 (2001): 950-8. doi:10.1007/s004150170047. 3 Bloem, Bastiaan R et al. 'Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena.' Movement disorders: official journal of the Movement Disorder Society vol. 19,8 (2004): 871-84. doi:10.1002/mds.20115. 4 Velseboer, Daan C., et al. 'Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis.' Parkinsonism & related disorders 17.10 (2011): 724-729 ; Parkinson's Foundation; CIA report; Company in to access your portfolio
